# Spectral AI, Inc.

Type: Company (MDAI)

Source: Healthcare Intelligence Brief — https://gethealthbrief.com/entity/spectral-ai-inc
Canonical HTML page: https://gethealthbrief.com/entity/spectral-ai-inc

## Timeline

- **2026-Q4**: Commercial Target — Anticipated focus on commercial scaling and market penetration for DeepView AI.
- **2026-03-24**: FY 2025 Earnings Release — Company reports $19.7M in total R&D revenue for the full year.
- **2026-03-24**: 2026 Guidance Introduced — Management provides first-ever revenue guidance for the upcoming fiscal year.
- **2025-12-31**: Year-End Cash Position — Spectral AI closes the year with $15.4 million in cash and equivalents.

## Recent coverage (2 stories)

### Spectral AI Reports $19.7M FY2025 Revenue, Eyes Growth with 2026 Guidance
2026-03-24 20:46:57 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Spectral AI reported full-year 2025 research and development revenue of $19.7 million, driven by its DeepView AI platform. With a strengthened cash position of $15.4 million, the company has introduced its first revenue guidance for 2026 as it transitions toward commercialization.
Full story: https://gethealthbrief.com/story/spectral-ai-fy2025-earnings-revenue-guidance

### Spectral AI Secures $31.7M BARDA Award for DeepView® AI Diagnostic System
2026-03-19 00:42:47 · Sentiment: Positive · Impact: 7/10 · Sources: 2

Spectral AI has been awarded $31.7 million in non-dilutive funding from BARDA to accelerate the development and clinical validation of its DeepView® System. This investment aims to enhance AI-driven medical diagnostics for faster, more accurate wound care decisions, particularly in burn and diabetic foot ulcer management.
Full story: https://gethealthbrief.com/story/spectral-ai-barda-funding-deepview-system

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://gethealthbrief.com/guides/methodology for the full editorial methodology.